There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
BACKGROUND / AIMS Silybum marianum is a herbal preparation commonly used by subjects with chronic hepatitis C ( CHC ) . The aims of this pilot study were to assess the efficacy and safety of S. marianum on serum hepatitis C virus ( HCV ) RNA , alanine aminotransferase levels and well-being in patients with CHC . METHODS Twenty-four subjects with CHC were enrolled into a r and omized , double-blind , placebo-controlled , crossover study . Subjects received 12 weeks of S. marianum ( either 600 mg or 1200 mg/day ) and placebo separated by a 4-week washout interval . Baseline biochemical , virological , psychological and quality -of-life tests were performed , with biochemical tests repeated monthly , and HCV RNA titer and quality -of-life and psychological assessment s repeated at the end of both treatment periods . RESULTS Seventeen patients completed the trial .  Mean changes in HCV RNA titers , serum ALT levels and Short Form-36 scores were not significantly different for subjects on S. marianum compared to those on placebo . There was no significant change in mean State-Trait Anxiety Inventory State-Anxiety scores on S. marianum from baseline . Adverse events were similar with S. marianum and placebo . CONCLUSIONS S. marianum is well tolerated in subjects with CHC , but does significantly affect serum HCV RNA , alanine aminotransferase levels , quality of life or psychological well-being in subjects with this condition
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .